Solara Active Pharma Sciences Limited — Updates, 06-02-2026: Press Release

Solara's Q3 performance was boosted by high-growth APIs (revenue ₹246.6 Cr, EBITDA ₹60.8 Cr, 24.7% margin). However, commodity Ibuprofen (revenue ₹102.4 Cr, EBITDA loss ₹23.4 Cr) dragged overall results. The board is evaluating options for Ibuprofen and reassessing the CRAMS split. Gross debt targets ₹499.9 Cr by May.